Good Ventures
VC Fund
San Francisco, United States
Good Ventures is a philanthropic foundation whose mission is to help humanity thrive.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Good Ventures invests in
Stages Good Ventures invests in
Countries Good Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Health Care 5 (42%)
- Biotechnology 4 (33%)
- Health Diagnostics 3 (25%)
- Medical 2 (17%)
- Energy 1 (8%)
Country
- United States 8 (67%)
- India 1 (8%)
- Denmark 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cari Tuna
President
|
President | Total investments: 0 | Find email | |
Dustin Moskovitz
Co-Founder & Board Member
|
Co-Founder & Board Member | Total investments: 20 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Helion Energy
|
Operator of a patented plasma accelerator technology designed to address the growing need for clean energy. The company's technology specializes in designing fusion generators based on magneto-inertial fusion with a fifty-megawatt module and energy regeneration, thereby enabling customers to use low-cost, clean, and safe energy. | $465M / Series G / Jun 04, 2026 | |
|
Helion Energy
|
Operator of a patented plasma accelerator technology designed to address the growing need for clean energy. The company's technology specializes in designing fusion generators based on magneto-inertial fusion with a fifty-megawatt module and energy regeneration, thereby enabling customers to use low-cost, clean, and safe energy. | $425M / Series F / Jan 28, 2025 | |
VenomAid Diagnostics
|
VenomAid Diagnostics is a company that provides clinically rapid diagnostic tests for snakebite envenoming. | $800K / Seed / Jan 29, 2024 | |
|
VenomAid Diagnostics
|
VenomAid Diagnostics is a company that provides clinically rapid diagnostic tests for snakebite envenoming. | $1M / Seed / Jan 25, 2023 | |
New Leaf Dynamic Technologies
|
New Leaf Dynamic Technologies is a cold chain solutions provider enterprise. | $770.2K / Seed / Sep 15, 2022 | |
Greenleaf Technologies
|
Greenleaf Technology is a distributor of spray nozzles and accessories. They provide products for airmix, turbo drop, ceramic, fertilizer, PWM systems, albuz orchards, and vineyard spray nozzles. | $933K / Seed / Apr 19, 2022 | |
Sherlock Biosciences
|
Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine thediagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results.SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States. | $80M / Series B / Mar 08, 2022 | |
Unravel Biosciences
|
Unravel Biosciences develops a vertically integrated computational platform to improve drug discovery. Unravel’s platform screens many drugs in parallel for their real-world impact (e.g., the complete gene expression profiles and resulting physiological changes), reversing this process to identify the likely target(s) a drug is interacting with. | $1.7M / Pre-Seed / Oct 10, 2021 | |
Olilux Biosciences
|
Olilux Biosciences provides medical diagnosis services that help in delivering tuberculosis detection alternatives. The company's first product is a novel small molecule called DMN-Tre, developed by Mireille Kamariza (Founder and CEO of OliLux) and Carolyn Bertozzi (Founder and Scientific Advisor) at Stanford University. | $400K / Grant / Jan 01, 2021 | |
Icosavax
|
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, whichit believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. | $6.5M / Grant / Aug 01, 2020 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Good Ventures invest in?
Good Ventures invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Seed and Grant stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Good Ventures?
Public channels for Good Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Good Ventures?
The team at Good Ventures includes Cari Tuna (President) and Dustin Moskovitz (Co-Founder & Board Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
